CFTR Modulator use and motor proficiency
Thirty-five individuals were receiving treatment with CFTR modulators at
the time of the BOT-2 assessment. Nine (26%) individuals reported using
ivacaftor, 25 (71%) lumacaftor-ivacaftor and 1 (3%)
tezacaftor-ivacaftor. Of note, data were collected prior to the approval
of elexacaftor-tezacaftor-ivacaftor. The median TMC for the group with
modulator use was 51 [IQR: 47 to 57] compared to a median 49 [IQR:
41 to 55] in those not receiving modulator therapy. There were no
observed differences in TMC or TMC% between those treated with
modulators compared to those not treated with modulators (p=0.0777,
p=0.0863 respectively).